A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.
暂无分享,去创建一个
H. Lenz | S. Tejpar | J. Novotny | T. André | M. Lei | K. Yamazaki | J. Ledeine | A. Paulson | S. Abdullaev